Yi Su

List of Publications by Year in descending order

107 papers	4,297 citations	186265 28 h-index	118850 62 g-index
118 all docs	118 docs citations	118 times ranked	6053 citing authors

#	Article	IF	Citations
1	Biomarker clustering in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 274-284.	0.8	2
2	Fine-tuning the cutpoint T-score as an epidemiological index with high specificity for osteoporosis: methodological considerations for the Chinese population. Quantitative Imaging in Medicine and Surgery, 2022, 12, 882-885.	2.0	7
3	Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	16
4	Investigating the Effect of Tau Deposition and Apoe on Hippocampal Morphometry in Alzheimerâ€™s Disease: A Federated Chow Test Model. , 2022, , .		1
5	Developing univariate neurodegeneration biomarkers with low-rank and sparse subspace decomposition. Medical Image Analysis, 2021, 67, 101877.	11.6	10
6	PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimerâ€™s disease-causing Presenilin-1 E280A mutation carriers. NeuroImage: Clinical, 2021, 31, 102749.	2.7	8
7	Preparation and characterization of DNA aptamers against roxithromycin. Analytica Chimica Acta, 2021, 1164, 338509.	5.4	7
8	Comparing amyloid-Î² plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. Acta Neuropathologica, 2021, 142, 689-706.	7.7	15
9	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. Neurology, 2021, 96, e1632-e1645.	1.1	16
10	Federated Morphometry Feature Selection for Hippocampal Morphometry Associated Beta-Amyloid and Tau Pathology. Frontiers in Neuroscience, 2021, 15, 762458.	2.8	5
11	Association between personality and tau-PET binding in cognitively normal older adults. Brain Imaging and Behavior, 2020, 14, 2122-2131.	2.1	21
12	The impact of dopamine D2-like agonist/antagonist on [18F]VAT PET measurement of VAChT in the brain of nonhuman primates. European Journal of Pharmaceutical Sciences, 2020, 143, 105152.	4.0	4
13	Applying surface-based morphometry to study ventricular abnormalities of cognitively unimpaired subjects prior to clinically significant memory decline. NeuroImage: Clinical, 2020, 27, 102338.	2.7	18
14	Quantifying the Effect of Financial Burden on Health-Related Quality of Life among Patients with Non-Hodgkinâ€™s Lymphomas. Cancers, 2020, 12, 3325.	3.7	11
15	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102491.	2.7	17
16	Cumulative and Incremental Value of Sarcopenia Components on Predicting Adverse Outcomes. Journal of the American Medical Directors Association, 2020, 21, 1481-1489.e3.	2.5	15
17	Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomalâ€Dominant Alzheimer's Disease Colombia Trial. Alzheimer's and Dementia, 2020, 16, 1023-1030.	0.8	15
18	Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. Lancet Neurology, The, 2020, 19, 513-521.	10.2	97

#	Article	IF	Citations
19	The Associations of Dietary Inflammatory Potential With Musculoskeletal Health in Chinese Community-Dwelling Older People: The Mr. OS and Ms. OS (Hong Kong) Cohort Study. Journal of Bone and Mineral Research, 2020, 37, 1179-1187.	2.8	15
20	Molecular Imaging Visualizes Recruitment of Inflammatory Monocytes and Macrophages to the Injured Heart. Circulation Research, 2019, 124, 881-890.	4.5	94
21	Persistent metabolic youth in the aging female brain. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3251-3255.	7.1	133
22	Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease. NeuroImage: Clinical, 2019, 22, 101767.	2.7	41
23	Comparison of Pittsburgh compound B and florbetapir in crossâ€sectional and longitudinal studies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 180-190.	2.4	84
24	Tau PET in autosomal dominant Alzheimerâ€™s disease: relationship with cognition, dementia and other biomarkers. Brain, 2019, 142, 1063-1076.	7.6	122
25	Quantitative positron emission tomography reveals regional differences in aerobic glycolysis within the human brain. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 2096-2102.	4.3	13
26	Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE Îµ4 genotype. Brain, 2018, 141, 1828-1839.	7.6	99
27	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurology, The, 2018, 17, 241-250.	10.2	383
28	Kinetic modeling of [¹⁸F]V<scp>AT</scp>, a novel radioligand for positron emission tomography imaging vesicular acetylcholine transporter in nonâ€human primate brain. Journal of Neurochemistry, 2018, 144, 791-804.	3.9	21
29	Crossâ€sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid Î² positron emission tomography pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 245-252.	2.4	49
30	Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. Neurobiology of Aging, 2018, 67, 95-98.	3.1	73
31	Self-Sterilizing and Regeneratable Microchip for the Precise Capture and Recovery of Viable Circulating Tumor Cells from Patients with Cancer. ACS Applied Materials & Interfaces, 2018, 10, 207-218.	8.0	27
32	ICâ€Pâ€009: COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD. Alzheimer's and Dementia, 2018, 14, P19.	0.8	0
33	ICâ€02â€01: THE RELATIONSHIP BETWEEN TAU PET AND AGE ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2018, 14, P1.	0.8	0
34	Widespread distribution of tauopathy in preclinical Alzheimer's disease. Neurobiology of Aging, 2018, 72, 177-185.	3.1	42
35	Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. NeuroImage: Clinical, 2018, 19, 406-416.	2.7	76
36	Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. Neurology, 2018, 91, e313-e318.	1.1	68

#	Article	IF	Citations
37	miR-330 regulates interleukin-13-induced MUC5AC secretion by targeting Munc18b in human bronchial epithelial cells. International Journal of Clinical and Experimental Pathology, 2018, 11, 3463-3470.	0.5	3
38	Loss of Brain Aerobic Glycolysis in Normal Human Aging. Cell Metabolism, 2017, 26, 353-360.e3.	16.2	228
39	AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. NeuroImage, 2017, 161, 171-178.	4.2	116
40	[ICâ€Pâ€057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P47.	0.8	0
41	Quantitative hemodynamic PET imaging using image-derived arterial input function and a PET/MR hybrid scanner. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1435-1446.	4.3	19
42	[P2â€“372]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P768.	0.8	0
43	[P1â€“008]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]â€AVâ€1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P233.	0.8	0
44	[P2â€“374]: TAU DISTRIBUTION IN PRECLINICAL ALZHEIMER'S DISEASE: FINDINGS FROM THE KNIGHT ALZHEIMER'S DISEASE RESEARCH CENTER. Alzheimer's and Dementia, 2017, 13, P769.	0.8	0
45	[ICâ€Pâ€054]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P44.	0.8	0
46	[ICâ€Pâ€061]: APOE4 EFFECT ON LONGITUDINAL VOLUMETRICS AND PIB ACCUMULATION IN PRECLINICAL ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P50.	0.8	0
47	[ICâ€Pâ€064]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2017, 13, P53.	0.8	0
48	[ICâ€Pâ€138]: CORTICAL THINNING PATTERN IN AUTOSOMAL DOMINANT AD PREDICTS AMYLOID POSITIVITY IN SPORADIC AD. Alzheimer's and Dementia, 2017, 13, P105.	0.8	0
49	[ICâ€Pâ€166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P125.	0.8	0
50	[ICâ€Pâ€205]: BRAIN AEROBIC GLYCOLYSIS AND TAU DEPOSITION WITH [18F]â€AVâ€1451 PET. Alzheimer's and Dementia, 2017, 13, P149.	0.8	0
51	[ICâ€02â€“02]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]â€AVâ€1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P4.	0.8	0
52	[P1â€“402]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2017, 13, P427.	0.8	0
53	[P1â€“422]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]â€AVâ€1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P440.	0.8	0
54	[P2â€“345]: APOE4 EFFECT ON LONGITUDINAL VOLUMETRICS AND PIB ACCUMULATION IN PRECLINICAL ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P754.	0.8	0

#	Article	IF	Citations
55	[O1â€“02â€“01]: CORTICAL THINNING PATTERN IN AUTOSOMAL DOMINANT AD PREDICTS AMYLOID POSITIVITY IN SPORADIC AD. Alzheimer's and Dementia, 2017, 13, P184.	0.8	0
56	[O1â€“02â€“03]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0
57	[O3â€“09â€“05]: BRAIN AEROBIC GLYCOLYSIS AND TAU DEPOSITION WITH [18F]â€AVâ€1451 PET. Alzheimer's and Dementia, 2017, 13, P922.	0.8	0
58	[O1â€“02â€“04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0
59	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimerâ€™s Disease: Results from the DIAN Study Group. PLoS ONE, 2016, 11, e0152082.	2.5	45
60	ICâ€Pâ€117: Neuronal Injury and Degeneration Evaluated With Imaging and CSF Biomarkers in Autosomal Dominant AD: Results From The Dian Study. Alzheimer's and Dementia, 2016, 12, P87.	0.8	0
61	P1â€254: Principal Component Analysis of [18F]â€Avâ€1451 TAU Pet in Alzheimerâ€™S Disease and Frontotemporal Dementia. Alzheimer's and Dementia, 2016, 12, P507.	0.8	0
62	ICâ€01â€03: Classifying TAU Pet Positivity With [18F]â€AVâ€1451 in Preclinical Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P2.	0.8	2
63	P3â€234: Similarities and Differences in Patterns of [F18]â€AVâ€1451 and [F18]â€FDG in Frontotemporal Dementia. Alzheimer's and Dementia, 2016, 12, P915.	0.8	0
64	IC-P-204: Principal Component Analysis of [18F]-Av-1451 TAU PET in Alzheimerâ€™s Disease and Frontotemporal Dementia. , 2016, 12, P145-P146.		0
65	ICâ€Pâ€206: Similarities and Differences in Patterns of [F18]â€Avâ€1451 And [F18]â€FDG in Frontotemporal Dementia. Alzheimer's and Dementia, 2016, 12, P147.	0.8	0
66	O2â€08â€05: Neuronal Injury and Degeneration Evaluated with Imaging and CSF Biomarkers in Autosomal Dominant Alzheimer's Disease: Results from the Dian Study. Alzheimer's and Dementia, 2016, 12, P246.	0.8	0
67	NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiology of Aging, 2016, 44, 1-8.	3.1	80
68	Longitudinal Î²-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Nonâ€“Alzheimer Disease Pathophysiology. JAMA Neurology, 2016, 73, 1192.	9.0	77
69	Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between Î²-Amyloid and Tauopathy. JAMA Neurology, 2016, 73, 1070.	9.0	246
70	Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. Annals of Neurology, 2016, 80, 379-387.	5.3	82
71	Tau and AÎ² imaging, CSF measures, and cognition in Alzheimerâ€™s disease. Science Translational Medicine, 2016, 8, 338ra66.	12.4	560
72	Heterogeneous multimodal biomarkers analysis for Alzheimerâ€™s disease via Bayesian network. Eurasip Journal on Bioinformatics and Systems Biology, 2016, 2016, 12.	1.4	18

#	Article	IF	Citations
73	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain, 2016, 139, 2249-2260.	7.6	150
74	Local and distributed PiB accumulation associated with development of preclinical Alzheimer's disease. Neurobiology of Aging, 2016, 38, 104-111.	3.1	15
75	Kinetics modeling and occupancy studies of a novel C-11 PET tracer for VAChT in nonhuman primates. Nuclear Medicine and Biology, 2016, 43, 131-139.	0.6	13
76	Impact of MR-Based Attenuation Correction on Neurologic PET Studies. Journal of Nuclear Medicine, 2016, 57, 913-917.	5.0	28
77	IC-P-051: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence. , 2015, 11, P41-P41.		0
78	P2-138: Early frame of PiB and FDG in autosomal dominant Alzheimer's disease: Similarity, discrepancy, and clinical implication. , 2015, 11, P538-P538.		0
79	IC-P-052: Comparison of cerebral glucose metabolism 18 F-FDG, early frames of 11 C-PIB,Âand cerebral blood flow 15 O-H2 O in autosomal dominant Alzheimer's disease. , 2015, 11, P41-P41.		0
80	P3-175: The ilp: A new tool for evaluating preclinical Alzheimer's disease using volumetric MRI in a single participant. , 2015, 11, P697-P697.		0
81	IC-P-100: The ILP: A new tool for evaluating preclinical Alzheimer's disease using volumetric MRI in a single participant. , 2015, 11, P68-P68.		1
82	IC-03-02: Early frame of PiB and FDG in autosomal dominant Alzheimer's disease: Similarity, discrepancy, and clinical implication. , 2015, 11, P8-P9.		0
83	Quantitative Amyloid Imaging Using Image-Derived Arterial Input Function. PLoS ONE, 2015, 10, e0122920.	2.5	30
84	Aerobic Glycolysis as a Marker of Tumor Aggressiveness: Preliminary Data in High Grade Human Brain Tumors. Disease Markers, 2015, 2015, 1-11.	1.3	25
85	P3-132: Comparison of cerebral glucose metabolism 18 F-FDG, early frames of 11 C-PiB, and cerebral blood flow 15 O-H2 O in autosomal dominant Alzheimer's disease. , 2015, 11, P674-P674.		0
86	IC-P-164: Patterns of tau binding in T807-PET imaging. , 2015, 11, P110-P110.		1
87	P2-154: Patterns of tau binding in T807-PET imaging. , 2015, 11, P546-P546.		0
88	O2-01-03: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence. , 2015, 11, P172-P172.		0
89	O5-06-06: Age-related decreases in tracer influx rate measured with PiB PET. , 2015, 11, P330-P330.		0
90	Preclinical evaluation of a promising C-11 labeled PET tracer for imaging phosphodiesterase 10A in the brain of living subject. NeuroImage, 2015, 121, 253-262.	4.2	16

#	Article	IF	Citations
91	MR-based attenuation correction for PET/MRI neurological studies with continuous-valued attenuation coefficients for bone through a conversion from R2* to CT-Hounsfield units. NeuroImage, 2015, 112, 160-168.	4.2	79
92	Partial volume correction in quantitative amyloid imaging. NeuroImage, 2015, 107, 55-64.	4.2	188
93	MRI based attenuation correction for PET/MRI via MRF segmentation and sparse regression estimated CT. , 2014, , .		5
94	IC-P-008: REGIONAL PIB DEPOSITION AND CSF AÎ²42 LEVELS SEVERAL YEARS PRIOR TO AMYLOID POSITIVITY. , 2014, 10, P11-P11.		0
95	Attenuation Effects of MR Headphones During Brain PET/MR Studies. Journal of Nuclear Medicine Technology, 2014, 42, 93-100.	0.8	16
96	Radiosyntheses and in vivo evaluation of carbon-11 PET tracers for PDE10A in the brain of rodent and nonhuman primate. Bioorganic and Medicinal Chemistry, 2014, 22, 2648-2654.	3.0	19
97	O2-05-04: REGIONAL PIB DEPOSITION AND CSF AB42 LEVELS SEVERAL YEARS PRIOR TO AMYLOID POSITIVITY. , 2014, 10, P173-P173.		0
98	IC-O2-01: How do we define amyloid positivity in an asymptomatic population? Comparison of CSF, quantitative PET and clinical PET examinations. , 2013, 9, P6-P6.		0
99	Regional variability of imaging biomarkers in autosomal dominant Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4502-9.	7.1	309
100	Noninvasive Estimation of the Arterial Input Function in Positron Emission Tomography Imaging of Cerebral Blood Flow. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 115-121.	4.3	45
101	Quantitative Analysis of PiB-PET with FreeSurfer ROIs. PLoS ONE, 2013, 8, e73377.	2.5	192
102	Inter-frame motion correction for small animal PET imaging. , 2011, , .		2
103	Single-Inputâ€“Dual-Output Modeling of Image-Based Input Function Estimation. Molecular Imaging and Biology, 2010, 12, 286-294.	2.6	12
104	A neural network to pulmonary embolism aided diagnosis with a feature selection approach. , 2010, , .		5
105	Wavelet denoising in voxel-based parametric estimation of small animal PET images: a systematic evaluation of spatial constraints and noise reduction algorithms. Physics in Medicine and Biology, 2008, 53, 5899-5915.	3.0	9
106	The application of maximum likelihood factor analysis (MLFA) with uniqueness constraints on dynamic cardiac microPET data. Physics in Medicine and Biology, 2007, 52, 2313-2334.	3.0	27
107	Single input multiple output (SIMO) optimization for input function estimation: a simulation study. , 2007, , .		0